Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126420) titled 'A clinical study on the efficacy and safety of neoadjuvant bemosubaimab combined with anlotinib in the treatment of locally advanced or unresectable clear cell renal cell carcinoma' on June 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Third Medical Centre, Chinese PLA General Hospital, Beijing, China
Condition:
Renal cell carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-06-15
Target Sample Size: Combined therapy group:40;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=320647
P...